Stock Events

Stock Events

Arrowhead Pharmaceuticals 

$57.77
102
-$3.54-5.77%Friday 02:38

Statistics

Day High
57.77
Day Low
57.23
52W High
87.5
52W Low
56.2
Volume
126
Avg. Volume
-
Mkt Cap
8.16B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 12Expected
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.52
-0.94
-0.36
0.22
Expected EPS
-1.517851
Actual EPS
N/A

Financials

-0.2%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
829.45MRevenue
-1.63MNet Income

Analyst Ratings

$100.46Average Price Target
The highest estimate is ⁦126.00⁩.
From 13 ratings within the last 6 months. This is not an investment recommendation.
Buy
77%
Hold
23%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ARWR.BOATS. It's not an investment recommendation.
NVIDIA
26
NVDA
Apple
24
AAPL
AMD
22
AMD
Tesla
21
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals is a direct competitor in the RNA interference (RNAi) therapeutic space, targeting similar diseases as Arrowhead.
Ionis Pharmaceuticals
IONS
Mkt Cap7.23B
Ionis Pharmaceuticals competes in the development of RNA-targeted therapies, sharing a focus on genetic and rare diseases.
Moderna
MRNA
Mkt Cap88.52B
Moderna is involved in mRNA therapeutics and vaccines, representing competition in the broader RNA-based treatment market.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech competes in the mRNA space, particularly in vaccines, but its technology could extend into therapeutic areas overlapping with Arrowhead's interests.
Sarepta Therapeutics
SRPT
Mkt Cap1.97B
Sarepta Therapeutics focuses on RNA-targeted treatments, especially for rare diseases, competing in the genetic medicine field alongside Arrowhead.
Arcturus Therapeutics
ARCT
Mkt Cap313.51M
Arcturus Therapeutics works on mRNA medicines for various diseases, including those in Arrowhead's target areas, making them competitors in RNA-based therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is focused on gene editing, a different but related approach to treating diseases at the genetic level, potentially competing for similar therapeutic indications.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is another company working on CRISPR-based gene editing, competing in the genetic medicine space where RNA therapies like Arrowhead's are also relevant.

About

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Show More
CEO
ISIN
US04280A1007

Listings

XETRA
DE
HDP1.XETRA
SA
BR
A2RR34.SA
STU
DE
HDP1.STU
MU
DE
HDP1.MU

0 Comments

Share your thoughts

FAQs

What is Arrowhead Pharmaceuticals stock price today?▼
The current price of ARWR.BOATS is $57.77 USD — it has decreased by -5.77% in the past 24 hours. Watch Arrowhead Pharmaceuticals stock price performance more closely on the chart.
What is Arrowhead Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Arrowhead Pharmaceuticals stocks are traded under the ticker ARWR.BOATS.
What is Arrowhead Pharmaceuticals market cap?▼
Today Arrowhead Pharmaceuticals has the market capitalization of 8.16B
When is the next Arrowhead Pharmaceuticals earnings date?▼
Arrowhead Pharmaceuticals is going to release the next earnings report on November 12, 2026.
What were Arrowhead Pharmaceuticals earnings last quarter?▼
ARWR.BOATS earnings for the last quarter are -1.36 USD per share, whereas the estimation was -1.28 USD resulting in a -6.53% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arrowhead Pharmaceuticals revenue for the last year?▼
Arrowhead Pharmaceuticals revenue for the last year amounts to 829.45M USD.
What is Arrowhead Pharmaceuticals net income for the last year?▼
ARWR.BOATS net income for the last year is -1.63M USD.
In which sector is Arrowhead Pharmaceuticals located?▼
Arrowhead Pharmaceuticals operates in the Other sector.
When did Arrowhead Pharmaceuticals complete a stock split?▼
The last stock split for Arrowhead Pharmaceuticals was on November 17, 2011 with a ratio of 1:10.